Grants & Programs

Immune Signatures in the Tumor and Beyond: Toward Predictive and Prognostic Markers

Date:
April 19, 2012
Time:
07:00 AM
Location:
Gaylord National Hotel and Convention Center, Washington, DC

On April 19-21, 2012 nearly 180 investigators from 50 academic and nonprofit organizations, 50 companies, and the FDA attended the CIC’s 2012 Scientific Colloquium at the Gaylord National Hotel and Convention Center in Washington, DC. The meeting, “Immune Signatures in the Tumor and Beyond: Toward Predictive and Prognostic Markers,” featured presentations by 30 field-leading experts, as well as a roundtable discussion on, “Benefit/Risk of Immunotherapy,” with members of the immunology and oncology communities participating.


Introduction

  • Axel Hoos, GlaxoSmithKline


Keynote Address

  • Wolf H. Fridman, Cordeliers Research Centre and Hopital European Georges Pompidou, University Paris Descartes, University Pierre et Marie Curie and INSERM,Paris


Host Reaction in Tumors

  • Pierpaolo Correale, Siena University Hospital
  • Padmanee Sharma, The University of Texas MD Anderson Cancer Center
  • Weiping Zou, University of Michigan Comprehensive Cancer Center, University of Michigan School of Medicine
  • Jerome Galon, Laboratory of Integrative Cancer Immunology, INSERM
  • Zaima Mazorra Herrera, Center of Molecular Immunology


Advances in Imaging

  • Dirk Jaeger, National Center for Tumor Diseases, University Medical Center Heidelberg
  • Michael L. Dustin, New York University School of Medicine
  • Steven M. Larson, Ludwig Center for Cancer Immunotherapy, Memorial Sloan-Kettering Cancer Center
  • Glenn Liu, University of Wisconsin Carbone Cancer Center
  • Philip S. Murphy, GlaxoSmithKline
  • Peter Friedl, Radboud University Nijmegen Medical Centre and University of Texas MD Anderson Cancer Center


Monitoring Therapeutic Immune Modulation

  • George Coukos, University of Pennsylvania
  • Lisa M. Coussens, Knight Cancer Institute, Oregon Health & Sciences University
  • Daniel E. Speiser, Ludwig Center for Cancer Research and Service of Radiation Oncology, University of Lausanne
  • Carl June, University of Pennsylvania
  • Thomas F. Gajewski, University of Chicago
  • Henry Hepburne-Scott, Serametrix Corporation
  • Carlos F. Santos, Biovest International Inc.
  • Jedd D. Wolchok, Memorial Sloan-Kettering Cancer Center


Benefit / Risk of Immunotherapy

  • Philip Kantoff, Dana-Farber Cancer Institute
  • Larry Norton, Memorial Sloan-Kettering Cancer Center
  • Vincent Brichard, GlaxoSmithKline Biologicals


Interdisciplinary Roundtable: Benefit / Risk of Immunotherapy

  • Vincent Brichard, GlaxoSmithKline Biologicals
  • James Gulley, National Institute of Health
  • Philip Kantoff, Dana Farber Cancer Institute
  • Larry Norton, Memorial Sloan-Kettering Cancer Center
  • Susan Slovin, Memorial Sloan-Kettering Cancer Center
  • Jedd Wolchok, Memorial Sloan-Kettering Cancer Center


CIC Immune Monitoring Activities

  • Michael Kalos, University of Pennsylvania School of Medicine
  • Lisa McNeil, Pfizer Inc.
  • Sebastian Attig, University of Mainz
  • Sylvia Janetzki, ZellNet Consulting
  • Cedrik Britten, Center for Translational Oncology at the University Medical Center (TRON)
  • Cecile Gouttefangeas, University of Tuebingen


Contact Us

Want to learn more about the Cancer Immunotherapy Consortium? Contact a CIC representative at consortium@cancerresearch.org or (212) 688-7515.